Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in advanced melanoma
NCT00086489Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2003
- Primary completion
- May 2007
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tremelimumab in melanoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety up to 2 years and Tumor response up to 2 years. Started Aug 2003; status: completed.
02
Drugs
tremelimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00086489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086489.